Access to essential mental health treatment is becoming increasingly difficult in Japan, as a key medication for attention-deficit/hyperactivity disorder faces an ongoing shortage.
Since last autumn, supplies of Concerta—a commonly prescribed drug for managing Attention-Deficit/Hyperactivity Disorder—have been running low across the country. The situation has forced clinics to make difficult adjustments, with some halting prescriptions for new patients altogether, while others are limiting existing patients to small, short-term doses due to constrained availability.
The medication is produced by Janssen Pharmaceutical, which had initially indicated that supply issues would be resolved within a couple of months. However, the shortage has persisted far longer than expected. Recent updates from the company suggest that it may take several more months before stock levels return to normal.
This prolonged disruption is raising concerns, particularly as the number of people diagnosed with ADHD continues to grow in Japan. In recent years, awareness of the condition has expanded, leading to more adults seeking diagnosis and treatment—adding further pressure to an already strained supply.
The challenge is compounded by limited treatment options. Concerta is one of only a small number of medications approved for adult ADHD in Japan, making it a critical component of care for many patients.
As demand rises and supply struggles to keep pace, the situation highlights broader issues around access to mental health treatment. For those relying on consistent medication to manage daily life, uncertainty over availability can have a significant impact—underscoring the need for more resilient healthcare solutions.